These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The ...

Get here Class 12th Biology paper pattern along with marking scheme and marks distribution for important topics.

Genetic testing has had a shift in the past ten years, as it has left medical laboratories and entered living rooms.

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk®Hereditary Cancer Test —the gold ...

Myriad Genetics (MYGN) announced MyRisk Hereditary Cancer Test-the gold standard in germline testing-has been expanded to include genes referenced ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and ...

Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, ...

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will exhibit its latest scientific research and findings in genetic testing at The National Society of Genetic ...

Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research ...

Myriad Genetics (MYGN) remains in the red, with losses having grown at an average annual rate of 21.1% over the last five years and no improvement in net profit margin compared to the prior year.